Notes: January 17, 2025, Enveric Biosciences, Inc. (the “Company”) filed a Certificate of Amendment of Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of Delaware to effect a 1-for-15 reverse stock split of the shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), either issued and outstanding or held by the Company as treasury stock, effective as of 8:00 a.m. (New York time) on January 27, 2025 The new CUSIP number for the Common Stock following the Reverse Stock Split is 29405E406.<p> July 14, 2022 -- Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 50 pre-split shares. The reverse stock split will become effective at 4:05 p.m., New York time, on Thursday, July 14, 2022Dec. 30, 2020 -- AMERI Holdings, Inc. (NASDAQ: AMRH) ("Ameri", the "Company"), announced a 1-for-4 reverse split of its common stock, effective as of 4:02 pm Eastern Time, December 30, 2020 (the "Reverse Stock Split"). Effective with the aforementioned completion of the Offer and other changes, a total of approximately 9.85 million shares of Enveric Biosciences common stock will be outstanding as of December 31, 2020, with the CUSIP number changing to 29405E 109. Such number of shares of Enveric Biosciences common stock outstanding does not include up to 3,525,407 shares of Enveric Biosciences common stock issuable upon conversion of 3,525,407 shares of Series B Preferred Stock expected to be outstanding as of December 31, 2020.<p> December 29, 2020 -- AMERI Holdings, Inc. (NASDAQ: AMRH) (“Ameri”, the “Company”), announced the voting results of the Special Meeting of stockholders that was held today. Based on the report from the Inspector of Elections, Ameri obtained sufficient votes for each proposal required to complete the previously announced proposed tender offer (the “Offer”), whereby Ameri will purchase all of the outstanding common shares of Jay Pharma Inc. (“Jay Pharma”) in exchange for shares of Ameri common stock, or if applicable, shares of Ameri preferred stock, at the exchange ratio set forth in the Tender Offer Support Agreement and Termination of Amalgamation Agreement dated August 12, 2020, among Ameri, Jay Pharma and certain other signatories thereto, as amended (the “Tender Agreement”), wherein Jay Pharma will become a wholly-owned subsidiary of Ameri, on the terms and conditions set forth in the Tender Agreement. Additionally, the previously announced spin-off of the IT services business of Ameri (the “Spin-Off”) was approved by the stockholders of Ameri. Ameri and Jay Pharma are targeting to complete the Offer and Ameri is targeting to complete the Spin-Off prior to the end of this calendar year, subject to Nasdaq approval of the listing of the shares of the post-Offer entity and the satisfaction or waiver of other closing conditions set forth in the Tender Agreement and the agreements related to the Spin-Off. Upon completion of the Spin-Off and the Offer, Ameri will change its name to Enveric Biosciences, Inc. and change its trading symbol on The NASDAQ Stock Market to “ENVB”. <p> November 22, 2019 -- AMERI Holdings, Inc. (Nasdaq: AMRH) (“Ameri100”), a specialized SAP® cloud, digital and enterprise solutions company, announced today that it will effect a reverse split of its common stock at a ratio of 1 for 25, effective Monday, November 25, 2019 (the “Effective Date”). The company’s common stock will begin trading on a split-adjusted basis when the markets open on the Effective Date under the existing trading symbol “AMRH.” The reverse stock split is primarily intended to bring the company into compliance with the minimum bid price requirement for maintaining its listing on the Nasdaq Capital Market. The new CUSIP number for the common stock following the reverse split will be 02362F302.